What is Welireg 40 mg, film-coated tablets used for?

( ARTG ) von Hippel-Lindau (VHL) disease associated tumours,WELIREG (belzutifan) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.,Advanced Renal Cell Carcinoma (RCC),WELIREG (belzutifan) is indicated for the treatment of adult patients with advanced renal cell carcinom

What are the side effects of Welireg 40 mg, film-coated tablets?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Can Welireg 40 mg, film-coated tablets be used during pregnancy?

( AHT ) For the active ingredient belzutifan You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Who manufactures Welireg 40 mg, film-coated tablets?

MSD Merck Sharp & Dohme AG (CH)

What ATC class does Welireg 40 mg, film-coated tablets belong to?

Welireg 40 mg, film-coated tablets: ATC L01XX74. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Welireg 40 mg, film-coated tablets

Data updated: 2026-04-11

Available in:

🇨🇿🇩🇪🇬🇧🇵🇹

Form

—

Dosage

—

Route

—

Storage

—

About This Product

Manufacturer

MSD Merck Sharp & Dohme AG

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.